Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost.
A real-world comparison finds similar overall survival in patients with refractory metastatic CRC treated with either regorafenib or trifluridine/tipiracil (TAS-102).